The investigation of GITR in Tregs as a potential target has revealed that the use of antibodies can facilitate the transformation of Tregs into CD4 + T cells, thereby diminishing their inhibitory impact on tumor immunity (Amoozgar et al., 2021). The gene discussed is CD4; the disease is neoplasm.